Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04968912 · ClinicalTrials.gov registry record · Phase 2
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT04968912 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 163 participants.
The verdict
NCT04968912, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
Interventions
- OTHER Placebo
- DRUG Nipocalimab
- DRUG Standard of Care Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2021-09-21 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04968912
The ClinicalTrials.gov registry entry for NCT04968912 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04968912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04968912 about?
NCT04968912 is a clinical study titled "A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)". The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
What is the current status of trial NCT04968912?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2021-09-21. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT04968912?
The interventions under investigation include: Placebo (OTHER), Nipocalimab (DRUG), Standard of Care Treatment (DRUG).
Who is sponsoring clinical trial NCT04968912?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.